**PRESS RELEASE**

**September 28, 2010 - Aipermon GmbH presents results of the ABC-program for the first time in the U.S. at the DMAA - The Forum 10 and Integrated Care Summit, October 13-15, 2010 in Washington D.C. The ABC program (Active Body Control) was developed by Professor Claus Luley at the University of Magdeburg, Germany. The program is designed for the treatment and management of type II diabetes utilizing Aipermon's AiperMotion™device and reporting software.**

The AiperMotion device, through its proprietary sensors, measures body activity in three dimensions, calculates the calories burned, and records the data along with an individualized basal metabolic rate (BMR). The device, which is worn on a belt or waistband, allows the patient to enter and track calories consumed and provides an instantaneous, ongoing analysis screen showing the 'balance' of calories burned vs. calories consumed. The data is then transmitted, typically weekly, via secure internet connection and is available for evaluation and feedback by a diabetes educator and/or wellness coach. This individualized feedback is central to changing behavior and promoting sustainable weight loss.

Study Results

The effectiveness of the ABC-program, utilizing the AiperMotion device, was demonstrated in a clinical study conducted at the University of Magdeburg. 88 patients with type II diabetes and a BMI 35.3 (average age 59 years) took part in a controlled, randomized study. Study participants were placed on a low-Glycemic, calorie restricted diet. All study participants were able to reduce their weight after six months. The mean weight loss was 10.3 kg (22.71 lbs.). It was considered to be a success if a participant reduced their weight by more than 5% of initial body weight. This was the case for 83% of the participants. 44% reduced their weights by more than 10% and 18% by more than 15%.

At the same time, biochemical and functional improvements were also achieved. Plasma glucose fell by 1.6 mmol/l (28.8 mg/dl) and A1c by 0.9% points. The proportion of patients with A1c > 7% decreased during the study from 66% to only 27% after six months. Improvements in A1c were achieved, while at the same time diabetic medication was reduced. The medical management of each patient was conducted by their primary care physician. Each physician was informed monthly regarding the course of the study and the laboratory values of each study participant.

For 67% of patients, diabetes medications were reduced or discontinued. For 30% (26 patients) there was a complete discontinuation of medications and for 38% (33 patients) a reduction. The ABC program also proved to be to be effective in sustaining results. The program was carried out for 12 months by 44 patients, for the others it ended after

6 months. After an additional 6 months the latter group had gained 1.4 kg (3 lbs.), but improvements in metabolic function and drug regime remained unchanged. The group, which participated for 12 months in the ABC program, maintained their weight reduction through an additional 6-months of follow-up. Overall, the ABC-program group averaged 3 times more weight loss than the control group.

For more information about the AiperMotion device and weight loss management of diabetic and pre-diabetic patients, please visit Aipermon at booth #320, or contact: Diane L. Hill, LDI Marketing, Inc., Phone: 617-504-6686, email: LDIMarketinginc@aol.com

## About Aipermon

Aipermon GmbH & Co. KG, based in Munich, Germany, is a provider of intelligent solutions in activity monitoring and telemonitoring. Aipermon's systems are used in disease state management programs, exercise intervention and disease prevention programs. Aipermon products include AiperSunny activity sensors and the energy balance computer AiperMotion 440TM. The company was honored in 2010 with the FIBO Innovation Award in the field of health promotion and was awarded the Technology Prize of "Initiative Germany – Land of Long Life".